Business Standard

A COMMERCIAL FEATURE

What's this ?

Commercial Feature is a Business Standard Digital Marketing Initiative.

The Editorial/Content team at Business Standard has not contributed to writing or editing these articles.

For further information, please write to assist@bsmail.in

Bain Capital & Cinven buy German generic drug maker Strada for € 4.1 bn

Stada offers a portfolio of high-quality, low-cost generic products including selected biosimilars

BS B2B Bureau  |  Bad Vilbel, Germany 

Bain Capital & Cinven buy German generic drug maker Strada for € 4.1 bn

Private equity firms and have jointly agreed to takeover Stada Arzneimittel AG, the Germany-based generic drug maker, in a € 4.1 billion bid.

Bain and have offered the shareholders of Stada a cash consideration of € 65.28 per share plus the 2016 dividend in the amount of € 0.72 per share as proposed by the management board of Stada resulting in a total offer value of € 66.00 per share. This offer represents an attractive premium of 48.9 percent over the closing price of 9 December 2016, the last trading day prior to the first specific rumours about a potential takeover of Stada appearing.

The offer estimates Stada’s equity value at approximately € 4.109 billion and the company's value at about € 5.318 billion.

“Our negotiating strategy over the last few weeks was very successful: We are very pleased that we have been able to increase the transaction value from approximately € 4.7 billion to more than € 5.3 billion by € 7.28 per share and have now reached the best offer for our shareholders. The offer of and contains the most attractive overall combination. In addition to the highest price we were able to reach comprehensive protection provisions especially for our employees and to initiate a future-oriented growth strategy,” said Ferdinand Oetker, chairman of the supervisory board of Stada Arzneimittel AG.

Stada offers a comprehensive portfolio of high-quality, low-cost generic products including selected The company has also built an attractive portfolio of well-established branded products, including the cold medicine Grippostad and the Ladival range of sun protection products. In 2016, Stada achieved adjusted group sales of € 2.167 billion, and adjusted net income of € 177.3 million.

RECOMMENDED FOR YOU

Bain Capital & Cinven buy German generic drug maker Strada for € 4.1 bn

Stada offers a portfolio of high-quality, low-cost generic products including selected biosimilars

Stada offers a portfolio of high-quality, low-cost generic products including selected biosimilars
Private equity firms and have jointly agreed to takeover Stada Arzneimittel AG, the Germany-based generic drug maker, in a € 4.1 billion bid.

Bain and have offered the shareholders of Stada a cash consideration of € 65.28 per share plus the 2016 dividend in the amount of € 0.72 per share as proposed by the management board of Stada resulting in a total offer value of € 66.00 per share. This offer represents an attractive premium of 48.9 percent over the closing price of 9 December 2016, the last trading day prior to the first specific rumours about a potential takeover of Stada appearing.

The offer estimates Stada’s equity value at approximately € 4.109 billion and the company's value at about € 5.318 billion.

“Our negotiating strategy over the last few weeks was very successful: We are very pleased that we have been able to increase the transaction value from approximately € 4.7 billion to more than € 5.3 billion by € 7.28 per share and have now reached the best offer for our shareholders. The offer of and contains the most attractive overall combination. In addition to the highest price we were able to reach comprehensive protection provisions especially for our employees and to initiate a future-oriented growth strategy,” said Ferdinand Oetker, chairman of the supervisory board of Stada Arzneimittel AG.

Stada offers a comprehensive portfolio of high-quality, low-cost generic products including selected The company has also built an attractive portfolio of well-established branded products, including the cold medicine Grippostad and the Ladival range of sun protection products. In 2016, Stada achieved adjusted group sales of € 2.167 billion, and adjusted net income of € 177.3 million.
image
Business Standard
177 22

Bain Capital & Cinven buy German generic drug maker Strada for € 4.1 bn

Stada offers a portfolio of high-quality, low-cost generic products including selected biosimilars

Private equity firms and have jointly agreed to takeover Stada Arzneimittel AG, the Germany-based generic drug maker, in a € 4.1 billion bid.

Bain and have offered the shareholders of Stada a cash consideration of € 65.28 per share plus the 2016 dividend in the amount of € 0.72 per share as proposed by the management board of Stada resulting in a total offer value of € 66.00 per share. This offer represents an attractive premium of 48.9 percent over the closing price of 9 December 2016, the last trading day prior to the first specific rumours about a potential takeover of Stada appearing.

The offer estimates Stada’s equity value at approximately € 4.109 billion and the company's value at about € 5.318 billion.

“Our negotiating strategy over the last few weeks was very successful: We are very pleased that we have been able to increase the transaction value from approximately € 4.7 billion to more than € 5.3 billion by € 7.28 per share and have now reached the best offer for our shareholders. The offer of and contains the most attractive overall combination. In addition to the highest price we were able to reach comprehensive protection provisions especially for our employees and to initiate a future-oriented growth strategy,” said Ferdinand Oetker, chairman of the supervisory board of Stada Arzneimittel AG.

Stada offers a comprehensive portfolio of high-quality, low-cost generic products including selected The company has also built an attractive portfolio of well-established branded products, including the cold medicine Grippostad and the Ladival range of sun protection products. In 2016, Stada achieved adjusted group sales of € 2.167 billion, and adjusted net income of € 177.3 million.

image
Business Standard
177 22